Cargando…

Metastasis-associated gene 1 (MTA1) enhances cisplatin resistance of malignant pleural mesothelioma by ATR-Chk1-mediated DNA repair

BACKGROUND: Malignant pleural mesothelioma (MPM) chemoresistance remains a challenge to oncologists. In our previous study, we demonstrated that the aberrant expression of metastasis-associated gene 1 (MTA1) is associated with carcinogenesis and metastasis in MPM. The aim of the present study was to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Caihua, Hu, Yufeng, Chen, Bin, Li, Dapeng, Liang, Rongrui, Shen, Meng, Wu, Mengyao, Tao, Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106096/ https://www.ncbi.nlm.nih.gov/pubmed/33987368 http://dx.doi.org/10.21037/atm-21-941

Ejemplares similares

Overexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in cancer
por: Liu, Kang, et al.
Publicado: (2021)

Targeting the ATR-CHK1 Axis in Cancer Therapy
por: Rundle, Stuart, et al.
Publicado: (2017)

Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression
por: Di Benedetto, Anna, et al.
Publicado: (2017)

Cdc6 contributes to cisplatin-resistance by activation of ATR-Chk1 pathway in bladder cancer cells
por: Chen, Sansan, et al.
Publicado: (2016)

Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapy
por: Manic, Gwenola, et al.
Publicado: (2015)

ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer
por: Li, Ching-Chia, et al.
Publicado: (2015)

Cerebral metastasis from malignant pleural mesothelioma
por: El Molla, Mohamed, et al.
Publicado: (2013)

Localized malignant pleural mesothelioma with renal metastasis
por: Zardawi, Sarah Jane, et al.
Publicado: (2015)

Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma
por: Goudar, Ranjit K
Publicado: (2008)

Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma
por: Borchert, Sabrina, et al.
Publicado: (2020)

Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer
por: Gorecki, Lukas, et al.
Publicado: (2021)

Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells
por: Johansson, D, et al.
Publicado: (2010)

Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion
por: Tsuji, S, et al.
Publicado: (2010)

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
por: van Haarst, J M W, et al.
Publicado: (2002)

MTA1 promotes metastasis of MPM via suppression of E-cadherin
por: Xu, Caihua, et al.
Publicado: (2015)

Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress
por: Saini, Priyanka, et al.
Publicado: (2015)

Inactivation of PRIM1 Function Sensitizes Cancer Cells to ATR and CHK1 Inhibitors()
por: Job, Albert, et al.
Publicado: (2018)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities
por: Sanjiv, Kumar, et al.
Publicado: (2015)

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities
por: Sanjiv, Kumar, et al.
Publicado: (2016)

Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy
por: Ahmed, Salman, et al.
Publicado: (2022)

Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma
por: Sørensen, J B, et al.
Publicado: (2008)

SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma
por: Salaroglio, Iris Chiara, et al.
Publicado: (2022)

PTBP1 enforces ATR-CHK1 signaling determining the potency of CDC7 inhibitors
por: Göder, Anja, et al.
Publicado: (2023)

Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition
por: Srinivasan, Gayathri, et al.
Publicado: (2017)

Interactions of Human Mismatch Repair Proteins MutSα and MutLα with Proteins of the ATR-Chk1 Pathway
por: Liu, Yiyong, et al.
Publicado: (2010)

MTA1 drives malignant progression and bone metastasis in prostate cancer
por: Kumar, Avinash, et al.
Publicado: (2018)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Malignant pleural mesothelioma: an update
por: Hajj, Glaucia N. M., et al.
Publicado: (2021)

Malignant pleural mesothelioma in situ
por: Ando, Kohei, et al.
Publicado: (2022)

The nucleolus stress response is coupled to an ATR-Chk1–mediated G2 arrest
por: Ma, Hanhui, et al.
Publicado: (2013)

Nuclear pCHK1 as a potential biomarker of increased sensitivity to ATR inhibition
por: Sundararajan, Vignesh, et al.
Publicado: (2022)

CTP sensing and Mec1(ATR)-Rad53(CHK1/CHK2) mediate a two-layered response to inhibition of glutamine metabolism
por: Ajazi, Arta, et al.
Publicado: (2022)

APE1 assembles biomolecular condensates to promote the ATR–Chk1 DNA damage response in nucleolus
por: Li, Jia, et al.
Publicado: (2022)

The Epithelial-to-Mesenchymal Transition (EMT) in the Development and Metastasis of Malignant Pleural Mesothelioma
por: Ramundo, Valeria, et al.
Publicado: (2021)

Inhibition of ATR-Chk1 signaling blocks DNA double-strand-break repair and induces cytoplasmic vacuolization in metastatic osteosarcoma
por: Li, Xiaoyang, et al.
Publicado: (2020)

Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma
por: Tabata, Chiharu, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_3phc9v0u67a28gt0gkj6ve9ru4